{"id":"NCT02322866","sponsor":"Almirall, S.A.","briefTitle":"Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety & Efficacy of Sarecycline in Treatment of Acne","officialTitle":"A Randomized, Multicenter, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of 1.5 mg/kg Per Day of Sarecycline Compared to Placebo in the Treatment of Acne Vulgaris","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-12-03","primaryCompletion":"2017-01-12","completion":"2017-01-12","firstPosted":"2014-12-23","resultsPosted":"2018-05-07","lastUpdate":"2019-02-01"},"enrollment":1034,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Acne Vulgaris"],"interventions":[{"type":"DRUG","name":"Sarecycline","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Sarecycline","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"To evaluate the efficacy and safety of an approximate 1.5 mg/kg/day dose of oral sarecycline compared to placebo in the treatment of moderate to severe facial acne vulgaris","primaryOutcome":{"measure":"Absolute Change From Baseline in Facial Inflammatory Lesion Counts at Week 12","timeFrame":"Baseline (Day 1) to Week 12","effectByArm":[{"arm":"Placebo","deltaMin":-10.7,"sd":0.5},{"arm":"Sarecycline","deltaMin":-15.1,"sd":0.6}],"pValues":[{"comp":"OG000 vs OG001","p":"< 0.0001"}]},"eligibility":{"minAge":"9 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":12,"exclusionCount":20},"locations":{"siteCount":57,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":513},"commonTop":[]}}